EPA0032 Autophagy and the acyl-coA-binding protein influence immune function in people living with HIVE-posterHost immune responses, vaccines and immunotherapies
EPA0033 Epistatic interaction of host immune factors modulates disease outcome following HIV infectionE-posterHost immune responses, vaccines and immunotherapies
EPA0034 Improvement of B cell responses by an HIV-1 amphiphilic polymer nanovaccineE-posterHost immune responses, vaccines and immunotherapies
EPA0035 HIV-infected macrophages express different NK ligands compared to HIV-infected T cellsE-posterHost immune responses, vaccines and immunotherapies
EPA0036 Pomalidomide drives expansion of HIV-specific CD8+ T-cells by promoting transcriptional activity of E2F1 and PRMT3E-posterHost immune responses, vaccines and immunotherapies
EPA0037 Zinc protein inhibitor SAMT-247 modulate immune response generated by ALVAC-based HIV vaccine candidate and improve the vaccine efficacyE-posterHost immune responses, vaccines and immunotherapies
EPA0038 Duration of antiretroviral therapy is a determinant of the frequency of NKG2C+CD57+ adaptive NK cells in persons living with cytomegalovirus and HIV infectionsE-posterHost immune responses, vaccines and immunotherapies
EPA0039 IL-15 treatment rescues perturbations to NK cell mitochondrial fitness and effector function driven by acute SIV infectionE-posterHost immune responses, vaccines and immunotherapies
EPA0040 Ibalizumab and CD4 domain 2 exert an allosteric effect on HIV envelope binding to CD4 domain1E-posterHost immune responses, vaccines and immunotherapies
EPA0041 Effect on time of SIVmac251 acquisition by passive administration of monoclonal antibodies recognizing SIV V2 in either the CH59-like coil/helical or the b-sheet conformationsE-posterHost immune responses, vaccines and immunotherapies
591 - 600 of 1427 items